The 3rd Targeted Radiopharmaceuticals (TRP) Summit returns at a crucial time for the entire industry. Spurred on by positive Phase III VISION trial data, there has been huge research investment, on both sides of the Atlantic, on how to deliver radiation therapy directly and specifically to tumours.
You can expect a wider array of insights from recent case studies to help you accelerate the development of the next generation of radioligand therapies from clinical approval to commercialisation.
As the only industry-led platform for discussing challenges and opportunities facing developers of theranostic radioligand therapies, we strive to tackle topics that are on every drug developer’s mind:
- How do we identify and validate new targets?
- Can we combine Targeted Radiopharmaceuticals with immunotherapy or other targeted oncology methods?
- How do we improve current clinical design methodologies and patient selection strategies?
- Where can improvements be made to the current supply and fulfilment models?
To know more visit: https://ter.li/r1oll2